Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0YTJNC
ADC Name
BA03-MCC-MMAE
Synonyms
BA03 MCC MMAE
   Click to Show/Hide
Organization
Shanghai Miracogen Inc.
Drug Status
Investigative
Indication
In total 3 Indication(s)
Colon cancer [ICD11:2B90]
Investigative
Lung cancer [ICD11:2C25]
Investigative
Rectal cancer [ICD11:2B92]
Investigative
Drug-to-Antibody Ratio
3.9
Structure
Antibody Name
BA03
  Antibody Info 
Antigen Name
Epidermal growth factor receptor (EGFR)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Effective Concentration (EC50) 
71.6
ng/mL
DiFi cells
Colorectal carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 71.60 ng/mL Positive EGFR expression (EGFR +++/++)
Method Description
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model Colorectal carcinoma DiFi cells CVCL_6895
References
Ref 1 Antibody-drug conjugate; 2016-08-25.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.